Then, we examine how viruses’ interference with VEGF signaling could be used against cancer, as exemplified by capsid immune platforms with VEGF-blocking peptides on their surfaces and by oncolytic vehicles that deliver targeted drugs including clinically validated specific anti-VEGF and VEGFR antibodies. The gene discussed is KDR; the disease is cancer.